SGAM
OMED

Smith Group Asset Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Smith Group Asset Management’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-48,790
Closed -$1.26M – 459
2015
Q1 		$1.26M Buy
+48,790
New +$1.24M 0.04% 165

Other funds holding OMED

ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Apex Capital Orinda, California $938M AUM 4.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Smith Group Asset Management's OMED Position: Q2 2015 in Review

Smith Group Asset Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2015, closing a stake of 48,790 shares — an estimated $1.26M sold.

Smith Group Asset Management first reported a position in OMED in Q1 2015 and held it in 1 quarter. The position peaked at $1.26M in Q1 2015. 83 funds tracked by Wall St. Rank hold OMED as of Q2 2015.

  • Smith Group Asset Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Smith Group Asset Management sold 48,790 OncoMed Pharmaceuticals, Inc. shares in Q2 2015, an estimated $1.26M.
  • Smith Group Asset Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q1 2015 and held it in 1 quarter.
  • Smith Group Asset Management's OncoMed Pharmaceuticals, Inc. position peaked at $1.26M in Q1 2015.
  • 83 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2015.

Based on Smith Group Asset Management's 13F filing for Q2 2015, filed 29 Jul 2015.